MASH

GSK buys phase III–ready liver drug in potential $2B deal to play in MASH arena
BioSpace
Wed, 05/14/25 - 09:46 am
GSK
Boston Pharmaceuticals
efimosfermin alfa
MASH
Wegovy treated a serious form of liver disease in a major clinical trial
NBC News
Mon, 05/5/25 - 11:06 am
Novo Nordisk
Wegovy
clinical trials
MASH
liver disease
Madrigal’s MASH drug sales again top Wall Street projections
BioPharma Dive
Thu, 05/1/25 - 10:13 pm
Madrigal Pharmaceuticals
Rezdiffra
earnings
MASH
Launch metrics of Madrigal's MASH drug Rezdiffra track 'exceptionally well,' CEO says
Fierce Pharma
Thu, 02/27/25 - 09:16 pm
Madrigal Pharmaceuticals
Rezdiffra
MASH
Its CEO died. The company scrapped a promising program. Now, for their 2nd act.
Pharma Voice
Thu, 02/27/25 - 10:12 am
Terns Pharmaceuticals
MASH
obesity
oncology
South Korean Biotech Firm Olix Exports MASH Treatment to Eli Lilly for 910 Billion Won
Business Korea
Mon, 02/10/25 - 10:24 pm
Eli Lilly
MASH
South Korea
Olix Pharmaceuticals
Akero's stock doubles as midphase MASH trial generates 'transformational' data: analyst
Fierce Biotech
Mon, 01/27/25 - 11:27 am
Akero Therapeutics
MASH
clinical trials
efruxifermin
Phase III MASH miss sends Galectin stock tumbling
BioSpace
Fri, 12/20/24 - 11:30 am
Galectin
clinical trials
MASH
belapectin
Novo Nordisk taps Photys for $186M cardiometabolic collab
Fierce Biotech
Wed, 12/18/24 - 11:21 am
Novo Nordisk
Photys
MASH
chronic kidney disease
Novo, Viking heat up MASH space with promising data at AASLD24
BioSpace
Wed, 11/20/24 - 11:40 am
Novo Nordisk
Viking Therapeutics
MASH
AASLD
GLP-1 agonists
semaglutide
VK2809
Boston Pharma hits phase 2 MASH goal, positioning monthly prospect to follow Akero, 89bio into pivotal trials
Fierce Biotech
Fri, 11/15/24 - 11:17 am
Boston Pharmaceuticals
clinical trials
MASH
efimosfermin alfa
Novo, with new results, to seek approval for obesity drug in MASH
BioPharma Dive
Fri, 11/1/24 - 11:25 am
Novo Nordisk
semaglutide
MASH
Gilead gives up on $15M MASH bet with Yuhan after mulling preclinical data
Fierce Biotech
Fri, 10/11/24 - 11:14 am
Gilead Sciences
Yuhan
MASH
How Madrigal plans to win on the market with the first MASH drug
Pharma Voice
Thu, 10/10/24 - 09:51 am
Madrigal Pharmaceuticals
MASH
Rezdiffra
Lilly, Insitro Ink Unique AI Deal, Eye Novel Treatments for Metabolic Diseases
BioSpace
Wed, 10/9/24 - 09:46 am
Insitro
Eli Lilly
siRNA
MASH
Boehringer kickstarts two Phase III trials as MASH therapy wins breakthrough status
Clinical Trials Arena
Tue, 10/8/24 - 09:56 am
Boehringer Ingelheim
MASH
clinical trials
survodutide
Madrigal's Rezdiffra off to strong start, but 'bumpiness' is coming: analyst
Fierce Pharma
Thu, 08/8/24 - 11:15 am
Madrigal Pharmaceuticals
Rezdiffra
MASH
Boehringer, Lilly face off in MASH at EASL
Pharmaphorum
Mon, 06/10/24 - 11:14 am
Eli Lilly
Boehringer Ingelheim
MASH
EASL
tirzepatide
survodutide
Boehringer, Zealand Heat Up MASH Race With Strong Phase II Data
BioSpace
Fri, 06/7/24 - 11:17 am
Boehinger Ingelheim
Zealand Pharma
survodutide
MASH
NASH
Boehringer, Zealand’s GLP-1 MASH Data ‘Unintentionally’ Published by Medical Congress Website
BioSpace
Thu, 06/6/24 - 11:48 am
Zealand Pharma
Boehringer Ingelheim
MASH
survodutide
clinical trials

Pages